A 6-month, open-label study of memantine in patients with frontotemporal dementia
A 6-month, open-label study of memantine in patients with frontotemporal dementia
复制标题
DOI：
10.1002/gps.1973
复制
发表时间：
2008-07-01
影响因子：
4
通讯作者：
Kurz, Alexander
中科院分区：
文献类型：
--
作者：
Diehl-Schmid, Janine;Foerstl, Hans;Kurz, Alexander
目的评价美金刚20 mg/d治疗额颞叶痴呆（frontotemporal dementia，FTD）的安全性及对患者认知行为的影响。结果在CIBIC加上基线后26周，16例患者中有4例最低限度改善，4例无变化，7例最低限度恶化，1例中度恶化。神经精神量表和额叶行为量表均未显示基线和最终访视之间的行为差异具有统计学意义。阿尔茨海默病评估量表总分增加，反映了认知能力的下降。执行功能，以及日常生活活动和锥体外系运动症状（EPMS）保持不变，在trial.Conclusion患者人数少，使统计检验的证据是有限的。因此，本研究只能显示药物作用的趋势。由于美金刚的耐受性良好，应进行进一步的随机对照研究以评估药物疗效。版权所有（C）2008约翰威利父子有限公司
Objective To evaluate safety and effects on cognition and behavior of memantine 20 mg/day in the treatment of patients with frontotemporal dementia (FTD).Methods This was a single-center, 6-month, open, uncontrolled study. Sixteen outpatients with a diagnosis of FTD were enrolled.Results On the CIBIC plus 26 weeks after baseline four of the 16 patients were minimally improved, four were unchanged, seven were minimally worse and one patient was moderately worse. Neither the Neuropsychiatric Inventory nor the Frontal Behavioral Inventory demonstrated statistically significant differences in behavior between baseline and final visit. There was an increase in the total Alzheimer's Disease Assessment Scale score, reflecting a decline in cognitive performance. Executive functions as well as activities of daily living and extrapyramidal motor symptoms (EPMS) remained unchanged during the trial.Conclusion The number of patients was small, so that the evidence given by statistical tests is limited. Thus, the present study can only show trends regarding drug effects. As memantine is well-tolerated, further randomized and controlled studies should be conducted to evaluate drug efficacy. Copyright (C) 2008 John Wiley & Sons, Ltd.